NO20074959L - Substituerte pyridinderivater - Google Patents
Substituerte pyridinderivaterInfo
- Publication number
- NO20074959L NO20074959L NO20074959A NO20074959A NO20074959L NO 20074959 L NO20074959 L NO 20074959L NO 20074959 A NO20074959 A NO 20074959A NO 20074959 A NO20074959 A NO 20074959A NO 20074959 L NO20074959 L NO 20074959L
- Authority
- NO
- Norway
- Prior art keywords
- pyridine derivatives
- substituted pyridine
- openers
- treatment
- general formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Foreliggende oppfinnelse vedrører pyridinderivater med den generelle formel I og deres anvendelse som åpnere av KCNQ-familien av kaliumionekanaler for behandlingen av CNS-lidelser. ?? ?? ?? ?? 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65842805P | 2005-03-03 | 2005-03-03 | |
DKPA200500321 | 2005-03-03 | ||
PCT/DK2006/000123 WO2006092143A1 (en) | 2005-03-03 | 2006-03-02 | Substituted pyridine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20074959L true NO20074959L (no) | 2007-10-02 |
Family
ID=36544250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20074959A NO20074959L (no) | 2005-03-03 | 2007-10-02 | Substituerte pyridinderivater |
Country Status (11)
Country | Link |
---|---|
US (2) | US7812020B2 (no) |
EP (2) | EP1861394A1 (no) |
JP (2) | JP5237643B2 (no) |
AU (1) | AU2006220130B2 (no) |
CA (1) | CA2599890C (no) |
CY (1) | CY1114561T1 (no) |
HR (1) | HRP20130973T1 (no) |
MX (1) | MX2007010547A (no) |
NO (1) | NO20074959L (no) |
PL (1) | PL2298766T3 (no) |
WO (1) | WO2006092143A1 (no) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7799832B2 (en) | 2003-10-23 | 2010-09-21 | Valeant Pharmaceuticals North America | Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains |
EP1861394A1 (en) * | 2005-03-03 | 2007-12-05 | H.Lundbeck A/S | Substituted pyridine derivatives |
US20070078177A1 (en) * | 2005-09-30 | 2007-04-05 | Washington University In St. Louis | Methods and compositions for treating non age related hearing impairment in a subject |
TWI453013B (zh) * | 2006-02-07 | 2014-09-21 | Lundbeck & Co As H | N-(2,4-二甲基-6-嗎啉-4-基-吡啶-3-基〉3,3-二甲基-丁醯胺之用途以及包含該化合物之醫藥品 |
US7960436B2 (en) | 2006-06-05 | 2011-06-14 | Valeant Pharmaceuticals International | Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators |
CA2661462C (en) | 2006-08-23 | 2015-09-29 | Valeant Pharmaceuticals International | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators |
US8993593B2 (en) | 2006-08-23 | 2015-03-31 | Valeant Pharmaceuticals International | N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators |
MX2009005652A (es) | 2006-11-28 | 2009-08-07 | Valeant Pharmaceuticals Int | Analogos 1,4 diamino biciclicos de retigabina como moduladores de canales de potasio. |
US8367684B2 (en) | 2007-06-13 | 2013-02-05 | Valeant Pharmaceuticals International | Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators |
US20100256145A1 (en) * | 2007-08-01 | 2010-10-07 | H. Lundbeck A/S | Use of kcnq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted |
US7786146B2 (en) | 2007-08-13 | 2010-08-31 | Valeant Pharmaceuticals International | Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators |
WO2010094644A1 (en) | 2009-02-17 | 2010-08-26 | Neurosearch A/S | Substituted pyridine derivatives and their medical use |
WO2010094645A1 (en) | 2009-02-17 | 2010-08-26 | Neurosearch A/S | Substituted pyridine derivatives and their medical use |
WO2010097379A1 (en) | 2009-02-24 | 2010-09-02 | Neurosearch A/S | Substituted pyrimidin derivatives and their medical use |
TWI504395B (zh) | 2009-03-10 | 2015-10-21 | Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier | |
TWI475020B (zh) | 2009-03-12 | 2015-03-01 | The substituted nicotine amide as a KCNQ2 / 3 modifier | |
TW201038565A (en) * | 2009-03-12 | 2010-11-01 | Gruenenthal Gmbh | Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators |
TWI461197B (zh) | 2009-03-12 | 2014-11-21 | 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier | |
US20120238547A1 (en) | 2009-09-07 | 2012-09-20 | Neurosearch A/S | 2, 3, 6 - triamino substituted pyridines as kv7 (kcnq) channel modulators |
WO2011026891A1 (en) | 2009-09-07 | 2011-03-10 | Neurosearch A/S | Substituted pyridine derivatives and their medical use |
NZ604745A (en) | 2010-08-27 | 2015-01-30 | Gruenenthal Chemie | Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators |
US8470852B2 (en) | 2010-08-27 | 2013-06-25 | Gruenenthal Gmbh | Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators |
EP2609086B1 (en) | 2010-08-27 | 2015-02-25 | Grünenthal GmbH | Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as kcnq2/3 modulators |
MX2013002295A (es) | 2010-09-01 | 2013-05-09 | Gruenenthal Gmbh | 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. |
KR101820645B1 (ko) * | 2010-10-20 | 2018-01-22 | 그뤼넨탈 게엠베하 | Kcnq2/3 조절제로서의 치환된 6아미노니코틴아미드 |
AU2015201122B2 (en) * | 2010-10-20 | 2016-02-25 | Grunenthal Gmbh | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators |
US9168259B2 (en) * | 2010-10-20 | 2015-10-27 | Grünenthal GmbH | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators |
CA2839350A1 (en) | 2011-07-05 | 2013-01-10 | Contera Pharma Aps | The use of serotonin receptor agonists for treatment of movement disorders |
AU2013248638A1 (en) | 2012-04-18 | 2014-12-04 | Grünenthal GmbH | Substituted 4-aminobenzamides as KCNQ2/3 modulators |
CA2950469C (en) | 2014-06-26 | 2022-09-20 | Contera Pharma Aps | Use of buspirone metabolites |
JP7100125B2 (ja) * | 2017-10-27 | 2022-07-12 | フレゼニウス・カビ・オンコロジー・リミテッド | リボシクリブおよびその塩の改善された調製のためのプロセス |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4200259A1 (de) | 1992-01-08 | 1993-07-15 | Asta Medica Ag | Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung |
WO1996021644A1 (en) * | 1995-01-10 | 1996-07-18 | Smithkline Beecham S.P.A. | Indole derivatives useful in the treatment of osteoporosis |
DE19539861A1 (de) | 1995-10-26 | 1997-04-30 | Asta Medica Ag | Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen |
EP1033366A3 (en) * | 1999-02-18 | 2000-12-27 | Pfizer Products Inc. | Amide derivatives useful as Neuropeptide Y (NPY) antagonists |
US6407120B1 (en) | 1999-02-18 | 2002-06-18 | Pfizer Inc. | Neuropeptide Y antagonists |
DE60037321T4 (de) * | 1999-08-04 | 2010-01-07 | Icagen, Inc. | Benzanilide als öffner des kaliumkanals |
US6495550B2 (en) * | 1999-08-04 | 2002-12-17 | Icagen, Inc. | Pyridine-substituted benzanilides as potassium ion channel openers |
US6117900A (en) | 1999-09-27 | 2000-09-12 | Asta Medica Aktiengesellschaft | Use of retigabine for the treatment of neuropathic pain |
WO2001092526A1 (en) | 2000-05-26 | 2001-12-06 | Bristol-Myers Squibb Company | Human kcnq5 potassium channel, methods and compositions thereof |
WO2001096540A2 (en) | 2000-06-11 | 2001-12-20 | Dupont Pharmaceuticals Company | Hepatitis c protease exosite for inhibitor design |
US6589986B2 (en) | 2000-12-20 | 2003-07-08 | Wyeth | Methods of treating anxiety disorders |
EP1361879A1 (en) * | 2001-02-20 | 2003-11-19 | Bristol-Myers Squibb Company | 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators |
JP2003206230A (ja) * | 2002-01-10 | 2003-07-22 | Yamanouchi Pharmaceut Co Ltd | シアノヘテロ環誘導体又はその塩 |
US7906537B2 (en) | 2003-03-21 | 2011-03-15 | H. Lundbeck A/S | Substituted p-diaminobenzene derivatives |
TWI357901B (en) | 2004-03-12 | 2012-02-11 | Lundbeck & Co As H | Substituted morpholine and thiomorpholine derivati |
EP1861394A1 (en) * | 2005-03-03 | 2007-12-05 | H.Lundbeck A/S | Substituted pyridine derivatives |
-
2006
- 2006-03-02 EP EP06706094A patent/EP1861394A1/en not_active Withdrawn
- 2006-03-02 EP EP10182072.8A patent/EP2298766B1/en active Active
- 2006-03-02 CA CA2599890A patent/CA2599890C/en not_active Expired - Fee Related
- 2006-03-02 PL PL10182072T patent/PL2298766T3/pl unknown
- 2006-03-02 JP JP2007557330A patent/JP5237643B2/ja not_active Expired - Fee Related
- 2006-03-02 AU AU2006220130A patent/AU2006220130B2/en not_active Ceased
- 2006-03-02 MX MX2007010547A patent/MX2007010547A/es active IP Right Grant
- 2006-03-02 US US11/817,340 patent/US7812020B2/en not_active Expired - Fee Related
- 2006-03-02 WO PCT/DK2006/000123 patent/WO2006092143A1/en active Application Filing
-
2007
- 2007-10-02 NO NO20074959A patent/NO20074959L/no not_active Application Discontinuation
-
2010
- 2010-09-14 US US12/881,263 patent/US8299071B2/en not_active Expired - Fee Related
-
2013
- 2013-02-26 JP JP2013036417A patent/JP5705249B2/ja not_active Expired - Fee Related
- 2013-10-14 HR HRP20130973TT patent/HRP20130973T1/hr unknown
- 2013-10-25 CY CY20131100948T patent/CY1114561T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
US7812020B2 (en) | 2010-10-12 |
CY1114561T1 (el) | 2016-10-05 |
US20110003811A1 (en) | 2011-01-06 |
AU2006220130B2 (en) | 2011-07-28 |
JP2008531609A (ja) | 2008-08-14 |
PL2298766T3 (pl) | 2014-09-30 |
JP5237643B2 (ja) | 2013-07-17 |
HRP20130973T1 (hr) | 2013-11-22 |
EP2298766A1 (en) | 2011-03-23 |
CA2599890C (en) | 2011-05-03 |
JP5705249B2 (ja) | 2015-04-22 |
AU2006220130A1 (en) | 2006-09-08 |
EP2298766B1 (en) | 2013-09-18 |
EP1861394A1 (en) | 2007-12-05 |
WO2006092143A1 (en) | 2006-09-08 |
US8299071B2 (en) | 2012-10-30 |
US20080318953A1 (en) | 2008-12-25 |
MX2007010547A (es) | 2007-10-03 |
CA2599890A1 (en) | 2006-09-08 |
JP2013136613A (ja) | 2013-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20074959L (no) | Substituerte pyridinderivater | |
NO20083427L (no) | Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse | |
NO20071843L (no) | Substituerte anilinderivater | |
NO20080675L (no) | P38-Map kinaseinhibitorer og metoder for deres anvendelse | |
NO20081434L (no) | 5-(fenylisoksazolyletoksy)-triazol-3-yl substituert pyridinsammensetninger for behandling av neurologisk, psykiatrisk eller smerteforstyrrelser | |
NO20083220L (no) | Heterocykliske derivater som modulatorer for ionekanaler | |
NO20055632L (no) | Aromatiske oksyfenyl- og aromatiske sulfanylfenylderivater | |
NO20082594L (no) | Pyrimidinylbenzotiofenforbindelser | |
NO20066055L (no) | Pyridinderivater | |
NO20062561L (no) | Kinoliner nyttige for behandling av kardiovaskulaere sykdommer | |
NO20060230L (no) | Nye aminobenzofenonforbindelser | |
NO20072963L (no) | 5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere | |
NO20063761L (no) | Sulfonamidderivater for behandling av sykdommer | |
NO20054905L (no) | 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika | |
NO20061137L (no) | Cyklopropylderivater som NK3-reseptorantagonister | |
NO20056192L (no) | Kapaseinhibitorer og anvendelse derav | |
NO20071642L (no) | N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger | |
NO20062021L (no) | Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika | |
NO20064325L (no) | Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes | |
NO20082496L (no) | Pyrazinderivater | |
ATE432260T1 (de) | Pyridinderivate als pkc-theta-hemmer | |
TW200720260A (en) | Prokineticin 1 receptor antagonists | |
TW200716566A (en) | Prokineticin 2 receptor antagonists | |
TW200728258A (en) | Novel compounds | |
NO20091463L (no) | Heterocyklisk deriverte metalloproteaseinhibitorer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CREP | Change of representative |
Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104 |
|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |